innoscripta SE (1INN) fair value: what the stock is really worth
As of Nov 6, 2026: fair value (intrinsic value) of innoscripta SE stock €118, price €44.15, upside +167.8%, quality 79 out of 100. Rating: strongly undervalued. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.
69 individual criteria per stock, every one traceableSee the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year. As of Nov 7, 2026.
How to read this chart
17‑month range €32.45 – €125.38 · fair‑value band €55.48 – €152.64 · the €44.15 price screens below the €118.24 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). As of Nov 7, 2026.
Follow innoscripta in your weekly email
Every Wednesday you see whether innoscripta is on track or worth a review, plus price against fair value. Free, up to 3 stocks.
We send you a confirmation link. Unsubscribe with one click.
innoscripta SE provides software-as-a-service for managing research and development (R&D) tax incentives and project management consulting in Germany and France.
Show moreShow less
It offers solutions for research and development documentation, such as human resources, task management, organization, project management, and time tracking.
It serves the additive manufacturing/3D printing; aerospace engineering; automotive; biotechnology; business consulting and technical services; chemical; construction; electrical engineering; energy; environmental technology and circular economy financial services/fintech; food and beverage; IT and software development; metal working; medical technology; mechanical engineering; manufacturing for industry; logistics; optical engineering and photonics; pharmaceutical; retail; research and development; textile industry/technical textiles; and professional, scientific, and technical services industries.
The company was incorporated in 2012 and is headquartered in Munich, Germany. innoscripta SE operates as a subsidiary of Hohenester Beteiligungs-Ug (Haftungsbeschränkt).
Stock analysis
innoscripta SE (1INN) currently trades at €44.15, while our model-based Fair Value estimate is €118.24, implying the stock looks roughly 63% undervalued today.
Show more
Valuation
Bull case: the Growth Earnings group reads highest at a median of €215.35 per share, and 21 of the 26 models we run sit above the €44.15 price.
Bear case: the Dividend Discount group reads lowest at €32.15, and 5 of the 26 models stay below the price. Data coverage for this calculation is high.
Scenario range: €55.48 (bear) to €152.64 (bull), the price of €44.15 sits below it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 79/100 (high quality), in the Technology sector.
Healthy Growth: Revenue growth appears healthy and is supported by profitability and cash-flow quality.
innoscripta SE reported revenue of €103M in FY2025 versus €27.3M in FY2022, a compound +55.9%/yr. Reported net income was €42.6M in FY2025, compounding +91.2%/yr from FY2022. FY2022 was a trough year, so the rate overstates the trend.
Key figures
Market cap €455M Small · P/E ratio 8.6 · P/S ratio 4.14 · EPS (TTM) €5.13 · Dividend yield 9.1% · Net margin 41.9% · Return on equity 156% · Return on assets (EBIT) 50.2% (4-year average).
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 92 out of 100 (low confidence).
What moves the price
The share trades about 59% below its 52-week high and 36% above its 52-week low, currently below its 200-day average.
For context, the median of 10 Technology peers we cover trades at 10% fair-value upside, at 168%, 1INN screens cheaper than that median.
Fair Value models
Bear€55.48Fair Value €118.24Bull€152.64
Price €44.15 · Upside +167.8%
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above starts from their evidence-weighted blend, not from a single model. In cyclical trough or peak years, after dilution or a stock split it is adjusted afterwards, so it can sit above or below the models. Based on fiscal year 2025 figures (about 10 months old). Earnings retained since then (€0.9690 per share) are deliberately not added.Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds.Coverage ⓘCoverage = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card.100/100
Revenue growth appears healthy and is supported by profitability and cash-flow quality.
Revenue growth 1 year
+59.8%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+55.9%
’22
’23
’24
’25
What shareholders gained per year (last 3 years) (mathematically smoothed) ⓘWhat the business itself delivers per year: earnings growth per share plus the dividend yield. This is what you get IF the market keeps valuing the stock the same way: it contains no assumption about the market changing its mind. Computed per share, so buybacks count and a merger does not pass as growth. For a company that pays no dividend it is pure earnings growth per share. Period: earnings growth per share as CAGR over the last 3 reported fiscal years (annual statements), plus the current dividend yield. The start value is the median of the three years around the start, so a single crisis year (a pandemic or a write-down) does not distort the rate. Smoothed = median of all growth paths between the years of the window (trend line on the logarithm of earnings per share): a single extreme year cannot distort the rate. The reported figure stays in the tooltip.
+106.0%
Earnings growth per share plus dividend.
Earnings per share, growth per year+96.9%
Dividend (yield on the price)9.1%
Profit margin 2022 to 2025 ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.34% → 61%
2025 sits 315% above its own trend. The rate follows the median trend of the last 3 years, not that single year.
Growth Forecast
Little optimism in the price
The price assumes less growth than the company has delivered so far.
What the price assumes ⓘThis turns our valuation around: instead of asking what the share is worth, it asks what growth the current price requires. It uses the cash the company keeps after all spending (free cash flow), the same discount rate as our models, five years of growth, then slowing evenly to 2 % a year by year ten. Compared with the analysts' sales forecasts extended to the same five years (at least three analysts, for context only, it does not enter the Fair Value): within 3 percentage points counts as "in line" (amber), below that little optimism (green), above that a lot of optimism (red).
−0.3%
The company could shrink this much every year for the next five years and today's price would still be justified.
What forecasts expect
n/a
No analyst forecast available.
After inflation (euro area: IMF forecast 2.2% a year to 2030, 2.6% from 2016 to 2025) that is about −2.4% a year for the price.
AI conclusion: Strong margins suggest possible pricing power as clients are added in new European markets via Clusterix, yet limited public evidence leaves durability and handling of claims unconfirmed amid reviews.
Main risk: Tax authority searches over research allowances pose the biggest risk by potentially exposing limits in the handling of client claims.
innoscripta keeps adding clients in new European markets through its Clusterix platform while independent experts review its documentation controls after tax authority searches over research allowances. Our models see the stock as undervalued. Will the platform's cross-border scalability and planned AI upgrades outweigh any fallout from the probes or expose limits in its handling of client claims?
Price, fair value, quality and upside side by side.
Free, no sign-up
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Software - Application · 628 stocks
Beats the industry median on 11/14 measures
Overall it ranks above its industry peers.
Valuation
Quality Score79 · Top 25%
Fair Value upside+167.8% · Top 25%
Profitability
Return on equity (12 months)156.5% · Top 25%
Return on assets42.2% · Top 25%
Net margin (12 months)41.9% · Top 25%
Operating margin (12 months)37.8% · Top 25%
Growth and dividend
Revenue growth (quarter YoY)23.2% · Top 25%
Dividend yield (12 months)9.1% · Top 25%
Balance sheet
Debt / equity0.20× · Above median
Valuation Multiplesvs Software - Application median · lower = cheaper
P/E (12 months)8.6× · Cheapest 25%
P/B9.42× · Priciest 25%
P/S (12 months)4.14× · Pricier than median
Price / free cash flow (fiscal year)12.5× · Cheaper than median
For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.
Cite: Fair Value Calculator (2026). "innoscripta SE Fair Value". https://www.fairvalue-calculator.com/stock/1INN
Frequently asked questions
Is innoscripta SE (1INN) overvalued or undervalued?
As of Nov 7, 2026, our model estimates a fair value of €118.24 versus a price of €44.15, about +168% upside (undervalued).
What is the fair value of 1INN?
Our model-based fair value for innoscripta SE is €118.24 (as of Nov 7, 2026), built from audited fundamentals. The current price: €44.15.
What is the quality score of 1INN?
innoscripta SE has a Quality Score of 79/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for innoscripta SE (1INN)?
Our model-based price target is the fair value of €118.24 (as of Nov 7, 2026) from 26 valuation models. Cautious scenario €55.48, optimistic scenario €152.64. It is a calculation from audited fundamentals, not an analyst target.
What is the innoscripta SE stock forecast for 2026?
Our models put fair value at €118.24, about +168% upside versus a price of €44.15 (undervalued). Cautious scenario €55.48, optimistic scenario €152.64. The calculation is refreshed regularly with new filings.
What is the revenue of innoscripta SE (1INN)?
innoscripta SE reported trailing-twelve-month revenue of about €122M (latest available figure, as of Nov 7, 2026).
Does innoscripta SE pay a dividend?
innoscripta SE currently shows a dividend yield of 9.06% relative to its recent price (as of Nov 7, 2026).
How much is the dividend of innoscripta SE (1INN) and when is the ex-dividend date?
innoscripta SE pays a dividend of €4.00 per share a year, a dividend yield of 9.1%. The last ex-dividend date was Apr 22, 2026. The payout ratio is 78.0% of earnings. Free cash flow covers the dividend 1.02 times. Our assessment: Sustainable. Payout and cash coverage both look sustainable.
What growth is priced into innoscripta SE (1INN)?
For today's price to be fair in a discounted-cash-flow model, innoscripta SE would have to grow free cash flow by -0.3 % per year for five years (discount rate 11.0 %, then slowing evenly to 2 % perpetual growth by year ten). Over the last 3 years revenue grew +55.9 % per year. As of Nov 7, 2026.
What discount rate (WACC) does the fair value of 1INN use?
Our models discount innoscripta SE at 11.0 %: a base by market capitalisation (small), country premium for Germany. The same rate applies in all 26 models.
What is a reverse DCF?
A reverse DCF turns the usual calculation around. Instead of deriving a value from assumptions, it takes today's price as given and asks: what free-cash-flow growth would a company have to deliver for exactly this price to be fair? The result is not a forecast but the expectation already priced in. For innoscripta SE that is -0.3 % per year for five years, then slowing evenly to 2 % by year ten, using the same discount rate (11.0 %) and the same formula as our fair value.
How much growth has innoscripta SE (1INN) delivered so far?
Over the past 3 years revenue at innoscripta SE grew +55.9 % a year. The price currently implies free-cash-flow growth of -0.3 % per year. Comparing the two shows how much confidence is in the price: if it demands more than has been delivered, the business has to accelerate for the maths to work.
How fast is the sector of innoscripta SE (1INN) growing?
The median revenue growth in the sector is +16.8 % a year. That is the yardstick for the growth priced into innoscripta SE (-0.3 % per year): it shows whether the expectation is within the usual range or beyond it.
What is the free cash flow yield of innoscripta SE (1INN)?
The free-cash-flow yield on the price is 9.20 %: that much free cash flow innoscripta SE produces per unit of market value. When it exceeds the discount rate of our models (11.0 %), the business already earns more than its cost of capital demands, and the price needs little additional growth.
What is the intrinsic value of innoscripta SE (1INN)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For innoscripta SE it is €118.24 per share (as of Nov 7, 2026), against a price of €44.15. It is the blended result of 26 valuation models in 8 families (DCF Models, Earnings-Based, Dividend Discount, Multiples, Asset-Based, Growth DCF, Economic Profit, Growth Earnings).
Is innoscripta SE stock overvalued or undervalued in 2026?
As of Nov 7, 2026, 1INN trades below its calculated fair value: price €44.15, fair value €118.24, a gap of about +168% (undervalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of 1INN?
No. The price is what the market pays today (€44.15); the fair value is what the company's own numbers justify (€118.24). For innoscripta SE the two are €74.09 per share apart. That gap is exactly why we show both numbers side by side.
How much is innoscripta SE worth?
The market values innoscripta SE at about €455M (market capitalisation, as of Nov 7, 2026). Per share that is €44.15; our models calculate a fair value of €118.24 per share.
What do the bullish and bearish scenarios say about 1INN?
Our models span a range for innoscripta SE: cautious scenario €55.48, base €118.24, optimistic €152.64 per share (as of Nov 7, 2026, price €44.15). The range comes from different growth and margin assumptions, not from analyst opinions.
What is the P/E ratio of 1INN?
innoscripta SE trades at a price-to-earnings ratio of 8.6 (as of Nov 7, 2026). A P/E on its own says little: it compares the price with ONE year of profit, while our fair value of €118.24 is built from several models across several years. Other multiples: P/B 9.4, P/S 4.1, EV/EBITDA 6.2.
How solid is the balance sheet of innoscripta SE (1INN)?
Balance-sheet figures for innoscripta SE (as of Nov 7, 2026): return on equity 156.5%, debt of 0.20 per unit of equity. They feed the Quality Score of 79/100, which measures business quality independently of the share price.
How far is 1INN from its 52-week high?
innoscripta SE trades at €44.15, about 59% below its 52-week high of €108.90 and 36% above the low of €32.45 (as of Nov 6, 2026). Distance from the high says nothing about value: that is what the fair value of €118.24 is for.
Which stocks are comparable to innoscripta SE?
From the same area (Technology) we also value SAP SE, Salesforce, Inc, Shopify Inc, ServiceNow, Inc, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is innoscripta SE stock attractive at the current price?
The data as of Nov 7, 2026: price €44.15, calculated fair value €118.24 (+168%), Quality Score 79/100, from 26 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of 1INN calculated?
We run innoscripta SE through 26 models from 8 families: DCF Models, Earnings-Based, Dividend Discount, Multiples, Asset-Based, Growth DCF, Economic Profit, Growth Earnings. Every model gets the same audited fundamentals; the fair value of €118.24 builds on their evidence-weighted average, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 13.3% above its aggregate fair value. innoscripta SE currently trades 63% below its own fair value, and the market average says nothing about that. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of innoscripta SE (1INN)?
The closing price on Nov 6, 2026 was €44.15. Our model-based fair value is €118.24, about +168% upside (undervalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with innoscripta SE right now?
The rarer combination: high quality (79/100) AND below fair value. That earns a closer look rather than a quick verdict. The price is below even our cautious bear case (€55.48). The market is more pessimistic than our downside scenario. The model range is unusually wide (€55.48 to €152.64). The outcome hinges heavily on assumptions, so read the point estimate with caution.
Key figures of innoscripta SE
How large is the market capitalisation of innoscripta SE (1INN)?
The market capitalisation of innoscripta SE is €455M. The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of innoscripta SE (1INN)?
The price-to-sales ratio of innoscripta SE is 4.14 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of innoscripta SE (1INN)?
Earnings per share at innoscripta SE are €5.13 (price ÷ EPS = P/E 8.6). Earnings per share over the last twelve months: total profit spread across every single share.
What is the dividend yield of innoscripta SE (1INN)?
The dividend yield of innoscripta SE is 9.1% (payout 78.0%). Yearly dividend relative to the share price. 3% pays 3 per 100 invested. Below: how much of profit is used for it.
What is the net margin of innoscripta SE (1INN)?
The net margin of innoscripta SE is 41.9% (last twelve months). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of innoscripta SE (1INN)?
The return on equity (ROE) of innoscripta SE is 156% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of innoscripta SE (1INN)?
On an EBIT basis the return on assets of innoscripta SE is 50.2% (avg 4y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of innoscripta SE (1INN)?
The operating margin of innoscripta SE is 37.8% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at innoscripta SE (1INN)?
Revenue at innoscripta SE is growing +23.2% versus a year earlier (3y avg +55.9%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at innoscripta SE (1INN)?
Earnings per share at innoscripta SE are growing +24.0% versus a year earlier. How much earnings per share grew versus a year earlier.
Free · no account needed
Watch innoscripta SE in the live analysis
One click puts innoscripta SE on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.
Broad data
Nov 7, 2026